Clinical Trial Update: A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 study of JNJ-64042056 in preclinical Alzheimer's disease is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• JNJ-64042056

Snippet

Sponsor: Janssen Pharmaceutica N.V., Belgium | Conditions: Preclinical Alzheimer's Disease | Phase 2 | Status: ACTIVE_NOT_RECRUITING